Results 1 to 10 of about 2,229 (127)

The Role of Anti-BP180 Antibody Monitoring in Bullous Pemphigoid: An Italian Single-Center Experience [PDF]

Dermatology Practical & Conceptual
Introduction: Bullous pemphigoid (BP) is the most common autoimmune blistering disorder, with anti-BP180 antibodies playing a key role in its pathogenesis and diagnosis. However, their utility in disease monitoring remains debated.
Giacomo Clarizio, Alice Massi, Stephano Cedirian, Tullio Brunetti, Alessio Natale, Andrea Gabusi, Federica Filippi, Camilla Loi, Lidia Sacchelli, Michelangelo La Placa, Bianca Maria Piraccini, Federico Bardazzi   +11 more
doaj   +2 more sources

Serum BP180 and BP230 autoantibodies in Alzheimer’s disease: diagnostic and cognitive associations in a retrospective study [PDF]

Frontiers in Aging Neuroscience
BackgroundTo assess the prevalence and diagnostic value of serum anti-BP180 and anti-BP230 antibodies in Alzheimer’s Disease (AD) and their relationship with cognitive function.MethodsWe conducted a retrospective case–control study comprising 279 ...
Sha Jin, Jie Yu, Huai-Li Liu, Cong Wang, Feng-Ming Zheng   +4 more
doaj   +2 more sources

BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid

Frontiers in Immunology, 2017
Bullous pemphigoid (BP) is by far the most common autoimmune blistering dermatosis that mainly occurs in the elderly. The BP180 is a transmembrane glycoprotein, which is highly immunodominant in BP. The structure and location of BP180 indicate that it is
Yale Liu, Liang Li, Yumin Xia
exaly   +3 more sources

Anti-BP180 Autoantibodies Are Present in Stroke and Recognize Human Cutaneous BP180 and BP180-NC16A

Frontiers in Immunology, 2019
Objective: Current evidence has revealed a significant association between bullous pemphigoid (BP) and neurological diseases (ND), including stroke, but the incidence of BP autoantibodies in patients with stroke has not previously been investigated.
Ya-Nan Wang, Xuming Mao, Di Wang
exaly   +3 more sources

BP230-Type Bullous Pemphigoid is a Rare Subset of Bullous Pemphigoid Associated With a Favorable Prognosis: A Retrospective Analysis From a Tertiary Referral Center. [PDF]

Int J Dermatol
International Journal of Dermatology, Volume 65, Issue 7, Page 1460-1462, July 2026.
Maglie R, Senatore S, Pipitò C, Baffa ME, Colabrese S, Visinoni S, Rubino V, Pira A, Mariotti F, Caproni M, Di Zenzo G, Antiga E.   +11 more
europepmc   +2 more sources

The Secretome of Bullous Pemphigoid IgG-Treated Keratinocytes Induces a Pro-Inflammatory Eosinophil Response. [PDF]

Exp Dermatol
ABSTRACT Bullous pemphigoid (BP) is an autoimmune blistering disease whereby the cutaneous antigens BP180 and BP230 are targeted by autoantibodies. Skin lesions in BP are characterized by an abundance of eosinophils. We recently demonstrated that the treatment of keratinocytes with antibodies from patients with BP induces a robust inflammatory response
Mansini AP, Bao L, Chhiba KD, Li J, Wang Y, Gainer H, McAlexander MA, McCrae C, Nazaroff CD, Kuang FL, Amber KT.   +10 more
europepmc   +2 more sources

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 and/or BP230 in basal keratinocytes.
Yosuke Mai, Kentaro Izumi, Nishie Wataru   +2 more
exaly   +3 more sources

Adjuvante Therapie des schweren und/oder refraktären bullösen Pemphigoids mit Immunadsorption – eine prospektive monozentrische Pilotstudie [PDF]

J Dtsch Dermatol Ges
Zusammenfassung Hintergrund und Zielsetzung Das bullöse Pemphigoid (BP) ist die häufigste blasenbildende Autoimmunerkrankung in der westlichen Welt. Während die Mehrheit der Patienten mit BP durch die langfristige Anwendung von Kortikosteroiden mit oder ohne Immunmodulatoren/Immunsuppressiva Remissionen erreicht, empfehlen nationale und internationale ...
Holtsche M, van Beek N, Hammers C, Vorobyev A, Kasperkiewicz M, Schumacher N, Muck P, Schmidt E.   +7 more
europepmc   +2 more sources

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption - A prospective monocenter pilot study. [PDF]

J Dtsch Dermatol Ges
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, Muck P, Schmidt E.   +7 more
europepmc   +2 more sources

Sita- and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross-sectional study. [PDF]

J Eur Acad Dermatol Venereol
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page e227-e230, April 2026.
Dräger S, Kauderer C, Meyhöfer S, Dräger L, Marquardt JU, Ludwig RJ, Arndt S, Boch K, Bieber K.   +8 more
europepmc   +2 more sources